

CURRICULUM VITAE

CHARLES V. SANDERS, M.D.

Office Address: Department of Internal Medicine
Louisiana State University School of Medicine
2020 Gravier Street
7th Floor, Suite D
New Orleans, LA 70112

Office Phone: (504) 568-5722

Fax: (504) 568-2127

E-mail: csande@lsuhsc.edu

Date of Birth: October 19, 1939

Place of Birth: Shreveport, Louisiana

Marital Status: Married (Julia)

Number of Children: Three

Education

B.S. – 1964: Louisiana College, Pineville, Louisiana (awarded coincident with the MD)

M.D. – 1964: Louisiana State University School of Medicine, New Orleans, Louisiana

Training and Positions Held

1964-1965: Rotating Internship
Confederate Memorial Medical Center
Shreveport, Louisiana

1965-1968: Resident in Internal Medicine
Confederate Memorial Medical Center
Shreveport, Louisiana

1968-1970: USPHS Fellowship in Infectious Diseases
Department of Internal Medicine
University of Texas Southwestern Medical School at Dallas
Dallas, Texas

1970-1975: Assistant Professor
Department of Internal Medicine
Louisiana State University School of Medicine
New Orleans, Louisiana

1975-1980: Associate Professor, Department of Internal Medicine
Chief, Section of Infectious Diseases
Louisiana State University School of Medicine
New Orleans, Louisiana

July 1980: Professor of Medicine
Chief, Section of Infectious Diseases

Department of Internal Medicine
 Louisiana State University School of Medicine
 New Orleans, Louisiana
 July 1988: Acting Head, Department of Medicine
 Professor of Medicine
 Chief, Section of Infectious Diseases
 Department of Internal Medicine
 Louisiana State University School of Medicine
 New Orleans, Louisiana
 July 1989-
 Present: Edgar Hull Professor and Chairman
 Department of Medicine
 Louisiana State University School of Medicine
 New Orleans, Louisiana
 January 1995-
 Present: Medical Director
 Medicine Hospital Center
 Charity and University Campuses
 Charity Hospital and Medical Center of Louisiana at New Orleans
 July 1998-
 Present: Professor of Microbiology, Immunology, and Parasitology
 Louisiana State University School of Medicine
 New Orleans, Louisiana

Major Research Interest

- Clinical and laboratory evaluation of newer antimicrobial agents in the treatment of aerobic and anaerobic infections

Hospital Appointments

- Senior Visiting Physician, Charity Hospital at New Orleans
- Consultant in Microbiology, Charity Hospital at New Orleans

Honors

- Alpha Omega Alpha
- Undergraduate Medical Society, LSU School of Medicine
- Phi Kappa Phi
- Best Clinical Professor, 1975
- Armine T. Wilson Memorial Lecturer, Wilmington Symposium, Delaware, 1986
- Quoted in March 23, 1987, issue of *Medical World News*
- Outstanding Clinical Professor, 1989-1990
- Best Overall Speaker, 12th Annual New Orleans Internal Medicine Board Review Course, 1990
- Listed as one of the 40 best doctors in the Infectious Disease Specialties of Internal Medicine in *The Best Doctors in America*, eds. Naifeh S, Smith G
- Chosen for first edition of *The Best Doctors in America: Southeast Region*, 1996-97, 1997-98

- Appeared on ABC's "20/20" for feature story on *Vibrio vulnificus*
- Appeared on Lifetime Medical Television's "Clinical Pearls in Infectious Disease, Parts I and II," June 1992
- Best Clinical Speaker, String of Pearls session of the New Orleans Internal Medicine Board Review Course, 1993
- LSU Medical Alumni Association Alumnus of the Year, 1995
- Chosen by LSU School of Medicine Classes of 1996, 1997, 1998, 1999, 2003, 2004, and 2006 to participate in Precommencement Hooding Ceremony
- Named Foreign Academic Correspondent, Section of Natural Sciences Royal Academy of Exact, Physical, and Natural Sciences Madrid, Spain, July 1996
- Named Laureate, Louisiana Chapter, American College of Physicians, 1997
- Named one of American College of Physicians/American Society of Internal Medicine's Top Ten Key Contacts, 2000-2001
- 2004 Orleans Parish Medical Society Award for Outstanding Achievement in Public Service/Education
- Listed in *New Orleans Magazine* as one of the Best Infectious Diseases Doctors in the city, August 2004
- Listed in *Louisiana Life* as one of the 2006 Top Louisiana Doctors in Infectious Disease, Autumn 2006

Other Activities

- Invited leader of China Delegation to the Peoples' Republic of China under the auspices of People to People International, 1983
- Co-chair with Kenneth E. Aldridge, M.D., of Symposium on Antimicrobials for the Infectious Disease Society of America, September 8, 2000

Certifications

- American Board of Internal Medicine
Diplomate: February 1970
Recertified: 1977
- American Board of Internal Medicine, Infectious Diseases
Diplomate: October 1972
- American Board of Internal Medicine, Geriatric Medicine
Certificate of Added Qualifications: 1994-2004
Recertified: 2004-2014

Professional Societies

Alliance for Academic Internal Medicine
 Alliance for the Prudent Use of Antibiotics
 American Association for Advancement of Science
 American Association of University Professors
 American Clinical and Climatological Association

American College of Physician Executives
 American College of Physicians Council, Louisiana Chapter
 American College of Physicians, Master
 American Federation for Medical Research
 American Foundation for AIDS Research
 American Geriatrics Society
 American Lung Association of Louisiana
 American Medical Association
 American Society of Internal Medicine
 American Society of Microbiology
 American Thoracic Society of Louisiana
 American Venereal Disease Association
 Association of American Medical Colleges
 Association of American Physicians
 Association for Practitioners in Infection Control
 Association of Professors of Medicine
 Infectious Disease Society of America, Fellow
 Infectious Disease Society, Louisiana-Mississippi Chapter
 Infectious Disease Society for Obstetrics and Gynecology
 Inter-American Society for Chemotherapy
 Louisiana State Medical Society
 Louisiana Society of Internal Medicine, Honorary Member, 1992
 New Orleans Southeastern Club
 Orleans Parish Medical Society
 Royal Society of Medicine
 Sigma Xi
 Society of General Internal Medicine
 South Central Association for Clinical Microbiology
 Southeastern Clinical Club
 Southern Infectious Disease Group
 Southern Medical Association
 Southern Society for Clinical Investigation
 Southwestern Association of Clinical Microbiology
 Southwestern Association of University Professors

Committees, Boards, and Offices

- Alliance for Academic Internal Medicine
 - Planning Committee, 2004 AAIM Forum for Chiefs and Chairs of Departments of Internal Medicine
 - Program Planning Committee, 2005
- American Clinical and Climatological Association
 - Audit Committee, 2006 Annual Meeting
- American College of Physicians
 - Vice-President, Louisiana-Mississippi Chapter

- 1992-Present
 - Chairman, Louisiana Chapter Credentials Committee
1994-1997
 - Member, Louisiana Chapter Program Committee
1995-1996
- American College of Physicians/American Society of Internal Medicine
 - Governor-elect, Louisiana Chapter
1998-1999
 - Governor, Louisiana Chapter
1999-2003
 - Board of Regents Membership Committee, 2001-2003
 - Membership Committee, 2001-Present
 - Scientific Program Committee 2004
- American Federation for Clinical Research/Southern Society for Clinical Investigation
Southern Section
Session Co-chair, Infectious Diseases II, February 9, 1998
- American Hospital Formulary Service Reference Panel Member
- American Medical Association Medical Student Section
Chapter Advisor for LSUMC, Fall 1998
- Association of American Medical Colleges
Section on Resident Education
Professional Development
- Association of Program Directors in Internal Medicine
- Association of Professors of Medicine
 - 1996 Winter Meeting Planning Committee
 - 2004 Academic Internal Medicine Week Special Session Planning Committee
 - Advocacy Advisory Board, February-March 2002 (2002 Winter APM Meeting)
 - Affiliate and Emeritus Members Committee
 - Board of Directors, July 1, 1998-June 30, 1999 and July 1, 2001-June 30, 2005
 - Chair, Constituency Task Force, 2002
 - Chair, Subcommittee on Editorials and Articles, July 1, 1998-June 30, 2000
 - Chair, Publications Committee, July 1, 1998-June 30, 1999
 - Meeting Planning Committee, 2004
 - Membership Task Force, 1997-1998
 - Nominating and Membership Committee, July 1, 2000-June 30, 2002
 - New Revenues Task Force, November 2002-Present
- Charity Hospital of Louisiana at New Orleans Medical Staff
 - Secretary/Treasurer, 1988-1989
 - Vice-President, 1990-1992
 - President, 1992-1994
 - Clinical Affairs Committee
 - Organization Steering Committee
- Charity Hospital of Louisiana at New Orleans
 - Antibiotic Audit Committee
 - By-Laws Committee
 - Local Board, 1992-1995

- Clinical Services Planning/Transition Committee, 1992
- Chairman, Credentials Committee, 1992-1994
- Executive Committee
- Family Medicine Development Task Force
- Friends of Charity
- General Clinical Research Center Advisory Committee
- Infection Control Committee
- Internal Medicine Committee
- Nutrition Committee
- Planning Committee
- Quality Assurance Committee
- Quality Care Committee
- Vascular Access Committee
- Editorial Board
 - *The American Journal of the Medical Sciences*, 2002-Present
 - *American Journal of Medicine*, 1996-2000
 - *Infectious Disease Practice*
 - *Journal of the Louisiana State Medical Society*, 2001-2005
 - *Patient Care*, 1989-1993
 - *Southern Medical Journal*, 1992-1995
 - Macmillan Healthcare Information
- Faith Baptist Church
 - Charter Member, 2001
 - Finance Committee, 2001
 - Founding Member, 2001
 - Trustee, 2001-2004
 - Chair, Finance Committee, 2003-2006
 - Pastor Selection Search Committee, 2003-2004
 - Property Search Committee, 2004
- FGP Cooperative Endeavor Agreement Revision Committee, September 2000
- Fitness and Wellness Facility Planning Committee, 1992
- Greater Baton Rouge Association of Health Care Providers
- Health Care Quality Alliance, Louisiana Chapter, 1992
- Hotel Dieu Hospital
 - By-Laws Committee
 - Chairman, Pharmacy Committee
 - Infection Control Committee
 - Long-Range Planning Committee, 1990-1991
 - LSU Advisory Council
 - Medical Staff Development Task Force
 - Member-at-Large, Executive Committee
- Infectious Disease Society of America Publication Committee, 1994-1996
- Louisiana State University
 - Advisory Committee, 1992

- Medical Alumni Association
 - Committee of 100
- Louisiana State University Dental School Infection Control Consultant
- Louisiana State University Health Sciences Center Bioterrorism Committee Chairman, October 2001-March 2002
- Louisiana State University Healthcare Network
 - Board of Directors, 1996-2002
 - Board of Directors Vice-President, 2002
 - Executive Committee, 1996-Present
 - Quality Improvement Committee, 2000
 - Overhead Allocation Committee, 2004
 - Preferred Provider Organization Steering Committee, 1988
 - Professional Practice Association Reorganization Subcommittee
 - Strategic Planning Committee, 2004
- Louisiana State University Medical Center
 - Ad Hoc Committee, February 1999 and August 2000
 - Allen Copping Teaching Award Nominations Committee, 1997-1998 and 2001-2002
 - Billing and Collections Committee, 1998
 - Clinical Education Building Space Utilization Committee, September 2000
 - Clinical Strategic Planning Committee, 2001
 - Committee on Faculty Development, 1997-1998
 - Committee to Make Recommendations on Center-Department Relationships, 1994
 - Compliance Oversight Committee, September 2001
 - Faculty Group Practice Board Executive Committee Vice-President, 1996
 - Foundation Advisory Board, 1993
 - Foundation Annual Fund Co-Chairman, 1993
 - Health Management Organization/Preferred Provider Organization Subcommittee
 - Institutional Graduate Medical Education Committee
 - Long-Range Planning Committee
 - Five-Year Planning Committee, 1992
 - Subcommittee on Finance
 - Extended 28-Year-Plan Group: Vision of the Year 2020
 - Louisiana Primary Health Care Initiative Committee
 - LSUHSC Mentor Program, Member – 2005
 - National Medical Enterprises – LSU Planning Committee
 - New Earl K. Long Hospital Planning Committee
 - Parking Committee Subcommittee
 - Professional Practice Association Managed Care Planning Subcommittee
 - Promotion Committee Chairman and Member, 1982-1987
 - Public Health Department Reactivation Feasibility Committee, 1993
 - Search Committee for Chief Executive Officer of University Hospital

- Space Committee
- Steering Committee for Molecular and Human Genetics
- Strategic Task Force Committee on Medical Education, 1988
- Student Disability Insurance Committee
- University Hospital Antibiotic Audit Committee
- University Medical Center Planning Committee, 1992
- Utilization Review Committee
- LSUMC/Tenet Negotiation Team
- Louisiana State University School of Medicine
 - Accelerated Program Faculty Committee
 - Administrative Council
 - Cancer Center Planning Committee
 - Cardiovascular Center of Excellence Steering Committee
 - Career Advisor – Student Government Association
 - Clinical Chairs Advisory Group
 - Clinical Chairs Advisory Working Group on Distribution of Clinical Funds, 1997-1998
 - Clinical Department Heads Committee
 - Clinical Sciences Research Building Advisory Committee
 - Committee on Women’s Affairs, 1996-1998 and 2003-2004
 - Compliance Oversight Committee, 2001
 - Consortium for Rural Primary Care, 1992
 - Cost Accounting Committee
 - Curriculum Committee
 - Dean’s Special Advisory Group
 - Disability Insurance for Students, Residents, and Fellows Committee
 - Primary Care Task Force, 1996
 - VAMC Dean’s Committee
 - Women in Medicine Committee
 - Organizing Subcommittee, 2002 Symposium
 - Organizing Subcommittee, 2003 Symposium
- Louisiana State University Department of Medicine
 - Residency Evaluation Committee
- Louisiana Area Health Education Center Planning Committee, 1990
- Medical Center of Louisiana at New Orleans
 - Case Management Advisory Committee, 1999
 - Chair, Transitional Unit Performance Improvement Team
 - Clinical Quality Management Committee
 - Screening and Assessment Committee
 - Search Committee for Chairman of Department of Family Medicine
 - Member, 1994
 - Chairman, 2001
 - Search Committee for Chairman of Obstetrics and Gynecology
Chairman

- Search Committee for Director of the Center for Cardiovascular Diseases and Chief of Section of Cardiology
Chairman
- Search Committee for Chairman of Radiology
- Staff Advisory Committee, Strategic Planning Initiative, 1999
- Transitional Planning Committee, MCLANO-Hotel Dieu
- Medical Meetings: Pearls & Perspectives on Internal Medicine, March 1999
- Mid-Course Correction Workshop
 - Education Committee, 1990
 - Strategic Planning Task Force Committee on Medical Education, 1989-1990
- New Orleans Academy of Internal Medicine
 - Treasurer, 1996-1997
 - Vice-President, 1997
 - President-elect, 1998
 - President, 1998-1999
- Orleans Parish Medical Society
 - Board of Governors, 1992-1994
 - Health System Reform Task Force
 - Executive Committee, 1996-1997
 - E.L. King Memorial Trust Fund Trustee, March 1996-November 1998
 - Finance Committee, 1996-1997
 - Membership Retention, Recruitment, and Development Subcommittee, 1996-1997
 - Service Bureau Treasurer, 1996-1997
 - Treasurer, 1996-1997
 - Long-Range Planning Committee, 1997
 - President, 1999-2000
 - Bioterrorism Committee, October 2001
- Reviewer
 - American College of Physicians
Infectious Diseases Medical Knowledge Self-Assessment Program (MKSAP)
syllabus, 2nd edition, 1996
 - American College of Physician Executives
Physician Executive
 - *American Journal of Epidemiology*
 - *American Journal of Medical Sciences*
 - *American Journal of Medicine*
 - *Annals of Internal Medicine*
 - *Archives of Internal Medicine*
 - *Clinical Infectious Diseases*
 - *Drug Investigation*
 - *Journal of Infectious Disease*
 - *Postgraduate Medicine*
 - *Western Journal of Medicine*

- Southeastern Louisiana Area Health Education Center (AHEC) Curriculum Committee
- Southern Society of Clinical Investigation
 - Councilor, 2004-2009
 - Nominating Committee, 2003-Present
 - Membership Committee, 2004-Present
- State of Louisiana Department of Health and Hospitals/LSUMC Partners Advisory and Technical Assistance Board, 1998

Grants

- Past Principal Investigator
National Institute of Health Grant No. A1 10282
Title: Host Factors Which Modify Human Interferon Responses
Total Funds: \$63,298
- Co-Investigator
National Institute of Health Grant (NIAID): 5-U01 AI27674-03
Title: AIDS Clinical Trial Unit
Total Funds: \$4.2 million
- Principal Investigator
Smith Kline & French Laboratories
Title: Comparison of the Safety and Efficacy of Ceftizoxime Versus Cefoxitin in the Treatment of Lower Extremity Infections in Diabetic Patients
Total Funds: \$22,555
- Principal Investigator
Miles Pharmaceuticals
Title: A Prospective, Open, Non-Comparative Study of Ciprofloxacin in the Treatment of Patients with Selected Tissue Infections
Total Funds: \$51,274
- Principal Investigator
Miles Pharmaceuticals
Title: Prospective Study of the Efficacy and Safety of Intravenous Ciprofloxacin in the Treatment of Selected Infections
Total Funds: \$56,617
- Principal Investigator
Miles Pharmaceuticals
Title: Mezlocillin Study
Total Funds: \$10,180
- Principal Investigator
Beecham Laboratories

Title: Open-Label Safety and Efficacy Study of Parenteral Timentin (Ticarcillin/
Clavulanic Acid) in the Treatment of Hospitalized Patients with Systemic or
Urinary Tract Infections

Total Funds: \$47,000

- Principal Investigator

Beecham Laboratories

Title: A Bacteriologically Controlled Comparative Study of the Safety, Tolerance, and
Efficacy of Timentin with Gentamicin/Clindamycin in the Treatment of
Hospitalized Patients with Intra-Abdominal Infections

Total Funds: \$151,000

- Principal Investigator

Beecham Laboratories

Title: An Open-Label, Non-Comparative Study of the Safety, Tolerance, and Efficacy of
Intravenous Timentin in the Treatment of Adult Hospitalized Patients with Intra-
Abdominal and/or Gynecologic Infections

Total Funds: \$7,500

- Principal Investigator

Wyeth Laboratories

Title: Open Multicenter Study of Intravenously Administered Cefpiramide in the
Treatment of Hospitalized Patients with Infections Caused by Susceptible Aerobic
and Anaerobic Bacteria

Total Funds: \$9,925

- Principal Investigator

Glaxo Inc.

Title: A Multicenter Randomized Evaluation of the Efficacy and Safety of Cefuroxime
Axetil and Cephalexin in the Treatment of Urinary Tract Infections

Total Funds: \$6,000

- Principal Investigator

Burroughs Wellcome Co.

Title: Efficacy and Safety of Septra I.V. Infusion Versus Claforan (Cefotaxime Sodium)
in the Treatment of Urinary Tract Infections

Total Funds: \$17,908

- Principal Investigator

Merrell Dow

Title: A Randomized Blinded Comparative Study of Teicoplanin Versus Vancomycin in
the Treatment of Vascular-Access Associated Bacteremia/Septicemia Caused by
Gram-Positive Organisms

Total Funds: \$5,400

- Principal Investigator
 Merrell Dow
 Title: An Open Study of Teicoplanin in the Treatment of Intravenous Drug Abuse
 Associated Endocarditis Caused by Gram-Positive Bacteria
 Total Funds: \$5,601

- Principal Investigator
 Merrell Dow
 Title: An Open Study of Teicoplanin in the Treatment of Acute Bone and Joint Infections
 Caused by Gram-Positive Bacteria
 Total Funds: \$6,514

- Principal Investigator
 XOMA
 Title: A Multicenter Trial to Determine the Safety and Efficacy of Antiendotoxin
 Antibody XMMEN-OE5 in the Treatment of Patients with Suspected Gram-
 Negative Bacteremia or Endotoxemia
 Total Funds: \$8,000

- Principal Investigator
 Stuart Pharmaceuticals
 Title: Comparison of Cefotetan and Cefotoxin in the Treatment of Post-Caesarean
 Section Endomyometritis
 Total Funds: \$104,881

- Co-Investigator
 Tulane University – Subcontract
 Title: AIDS Treatment and Evaluation Unit
 Total Funds: \$192,326

Publications

Abstracts and Preliminary Notes

1. Sanders CV, Luby JP, Johanson WG, Barnett JA, Sanford JP. An outbreak of nosocomial infections due to *Serratia marcescens* traced to contaminated inhalation-therapy medication. Abstract No. 150. *J Lab Clin Med* 74:1005, 1969.

2. Gilbert DN, Kutscher E, Sanders CV, Luby JP, Barnett JA, Sanford JP. The apparent emergence of non-nosocomial/nosocomial wound infections: a study of tornado casualties. *J Lab Clin Med* 76:999, 1970.

3. Sanders CV, Luby JP, Sanford JP. Suppression of interferon response in uremic lymphocytes. *Clin Res* 18:446, 1970.

4. Repath F, Sanders CV, Dascomb HE. An agar plate capillary rod method for testing antibiotic sensitivity of bacteria. *Clin Res* 20:83, 1972.
5. Lewis AC, Sanders CV, Mickal A, Redmond K, Torres J. Anaerobic microflora of the endocervix in healthy women and women with abnormal papanicolaou (Pap) smears. South Central Branch of the American Society for Microbiology. Hattiesburg, Mississippi. October 11-12, 1974.
6. Sanders CV, Mickal A, Lewis AC, Torres J. Anaerobic flora of the endocervix in women with normal versus abnormal papanicolaou (Pap) smears. *Clin Res* 23:30A, 1975.
7. Sanders CV. Localization of site of urinary tract infection by detection of antibody-coated bacteria in urine. South Central Branch of American Society for Microbiology. New Orleans, Louisiana. March 21, 1975.
8. Hanna BJ, Sanders CV, Lewis AC, Williams WL, Sands ML. Treatment of anaerobic infections with metronidazole. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. October 27-29, 1976.
9. Rojas M, Williams WL, Jones RJ, Taylor S, Sanders CV, Dascomb HE, Boudreaux V. Experience with *Mycobacterium kansasii* infection occurring in employees of a large general hospital. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. October 27-29, 1976.
10. Burlington DB, Sanders CV. The effects of aspirin and prostglandins on lymphocyte interferon production. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. October 27-29, 1976.
11. Bracis R, Sanders CV, Kimbrough R, Gilbert DN. Methicillin hemorrhagic cystitis. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. October 27-29, 1976.
12. Sands M, Torres J, Sanders CV. In vitro sensitivity of *Mycobacterium marinum* to minocycline and doxycycline. Seventy-seventh Annual Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 8-13, 1977.
13. Ivens MS, Singleton B, Sanders CV. Experiences with skin testing of hospital patients with antigenic substances derived from *Sporothrix schenckii*. South Central Branch, American Society for Microbiology. Jackson, Mississippi. October 21-22, 1977.
14. Singleton B, Ivens MS, Sanders CV. Studies with skin testing of hospital patients with antigenic substances derived from *Sporothrix schenckii*. Minority Biomedical Support Symposium. Atlanta, Georgia. March 27-29, 1978.
15. Torres-R J, Swenson RM, Hanna B, Lorber B, Sanders CV. Treatment of anaerobic infections with tiarcillin, clinical and laboratory aspects. Eighteenth Interscience

- Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia. October 1-4, 1978.
16. Greenberg RN, Scalcini MC, Sanders CV. Cefamandole therapy for anaerobic infections. Eighteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia. October 1-4, 1978.
 17. Greenberg RN, Sanders CV, Lewis AC, Shaik LM. Localization of urinary tract infection in the adult non-pregnant female. *Clin Res* 26:769A, 1978.
 18. Moss SW, Sanders CV. Adherence of *Escherichia coli* to human vaginal cells mediated by mannose receptors in women with recurrent urinary tract infection. *Clin Res* 26:770A, 1978.
 19. Singleton B, Ivens MS, Sanders CV. Cutaneous hypersensitivity to sporotrichin in hospital patients and other population groups. VII Congress of the International Society for Human and Animal Mycology. Jerusalem, Israel. March 11-16, 1979.
 20. Sanders CV, Hanna BJ, Lewis AC, Scalcini M. The use of metronidazole in the treatment of anaerobic pleuropulmonary infections. The Second International Metronidazole Conference. Geneva, Switzerland. April 25-27, 1979.
 21. Sanders CV, Shaik LM, Marier RL, Lehmann HP. Rapid assay of gentamicin in serum by the enzyme multiplied immunoassay technique (EMIT). Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, Massachusetts. October 1-5, 1979.
 22. Greenberg RN, Sanders CV, Shaik LM, Marier RL, Lewis AC, Moise P. Single dose therapy of urinary tract infections with cefaclor. *Clin Res* 27:751A, 1979.
 23. Torres-R JR, Stratton CW, Sanders CV, Horsman TA, Hawley HB, Dascomb HE, Vial LJ. Candidal suppurative peripheral thrombophlebitis. *Clin Res* 27:754A, 1979.
 24. Sande MA, Korzeniowski OM, Endocarditis Collaborative Group (including CV Sanders), UVA Medical School, Charlottesville, VA. Comparison of nafcillin + gentamicin (NG) in the treatment of addicts with *S. aureus* endocarditis. Nineteenth Interscience Conference on Antimicrobial Agents and Chemotherapy. October 1-5, 1979.
 25. Palmisano B, Marier RL, Pan YJ, Bernstein D, Sanders CV, Ragan FA, Saum R. Stat gentamicin levels in premature infants by latex agglutination inhibition. Conference of the American Society of Microbiology. September 1980.
 26. LeGrand P, Bordelon JY, Gewin WC, Sanders CV. The telescoping plugged catheter in suspected anaerobic infections: a controlled series. American Thoracic Society/American Lung Association Annual Meeting. Washington, D.C. *Am Rev Resp Dis* 121:157, 1980.

27. Marier RL, Sanders CV. Piperacillin versus carbenicillin in the therapy of severe infections. Twentieth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 22-24, 1980.
28. Greenberg RN, Sanders CV, Marier RL, Shaik LM, Moise P, Lewis AC. Single-dose therapy of urinary tract infection with cefaclor. Twentieth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 22-24, 1980.
29. Zide MF, Sanders CV, Marier RL, Scalcini MS. Treatment of hospitalized patients with severe odontogenic infections with cefuroxime. Twentieth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 22-24, 1980.
30. Sanders CV, Shaik LM, Marier RL, Lehmann HP. Rapid assay of gentamicin in serum by the enzyme multiplied immunoassay technique. Proceedings of the Eleventh International Congress of Chemotherapy. October 1-5, 1980.
31. Aldridge KE, Sanders CV, Marier RL. Comparison of the susceptibility of anaerobic bacteria to various beta-lactam antibiotics. Eighty-first Annual Meeting of the American Society for Microbiology. Dallas, Texas. March 1-6, 1981.
32. Martin DA, Sanders CV. N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobes. Eighty-first Annual Meeting of the American Society for Microbiology. Dallas, Texas. March 1-6, 1981.
33. Sanders CV. Piperacillin versus carbenicillin in the therapy of serious infections. Problem Pathogens and Serious Infections: Management with Piperacillin. Florence, Italy. July 19, 1981.
34. Marier RL, Sanders CV, Williams W, Derks F, Faro S, Dabezies E, Aldridge K. Piperacillin versus carbenicillin in the therapy of severe infections. Twelfth International Congress of Chemotherapy. Florence, Italy. July 19-24, 1981.
35. Marier RL, Faro S, Sanders CV, Williams W, Derks F, Aldridge K. Moxalactam in the therapy of serious infections. Twelfth International Congress of Chemotherapy. Florence, Italy. July 19-24, 1981.
36. Emison JW, Zide MF, Sanders CV. Treatment of fifty hospitalized patients with severe odontogenic infections with cefuroxime. Sixty-third Annual Meeting, American Association of Oral and Maxillofacial Surgeons. Washington, D.C. September 18-22, 1981.
37. Martin DA, Aldridge KE, Janney A, Sanders CV, Marier RL. In vitro sensitivity patterns of *Bacteroides fragilis* to fifteen antimicrobial agents and occurrence of beta-lactamase

- production. American Society for Microbiology, South Central Branch. New Orleans, Louisiana. October 23-24, 1981.
38. Levison ME, ALA Collaborative (including CV Sanders). Penicillin (P) versus clindamycin (C) treatment of anaerobic lung abscess (ALA). Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. November 4-6, 1981.
 39. Chambers HF, Korzeniowski OM, Sande MA, National Collaborative Endocarditis Study Group (including CV Sanders). Clinical manifestations of *Staphylococcus aureus* endocarditis. Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. November 4-6, 1981.
 40. Dismukes WE, Graybill JR, Steven DA, Shadomy S, Cloud C, Horton R, Cryptococcal Meningitis Study Group (including CV Sanders). Phase II studies on ketoconazole (K). Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. November 4-6, 1981.
 41. Espinel-Ingroff A, Shadomy S, Porter D, Steltz M, Dismukes WE, the CMSC Group (including CV Sanders). Ketoconazole: serum levels as determined by bioassay (BA) and HPLC. Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. November 4-6, 1981.
 42. Shadomy S, Yu HP, White SC, Dismukes WE, CMCS Group (including CV Sanders). Ketoconazole: susceptibility testing of clinical isolates of pathogenic fungi. Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. November 4-6, 1981.
 43. Marier RL, Aldridge KE, Sanders CV. The role of anaerobes in sinus and middle ear infection: implications for the future. First United States Metronidazole Conference. Tarpon Springs, Florida. February 19-21, 1982.
 44. Sanders CV, Aldridge KE, Marier RL. Diagnosis of anaerobic infections. First United States Metronidazole Conference. Tarpon Springs, Florida. February 19-21, 1982.
 45. Marier RL, Aldridge KE, Martin D, Derks F, Williams W, Janney A, Sanders CV. Thienamycin versus cefazolin in vivo. Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy. Miami, Florida. October 4-6, 1982.
 46. Stith HD, Zide MF, Sanders CV, Aldridge KE, Marier RL. Parenteral and oral cyclacillin in treatment of mild to severe maxillofacial infections. Sixty-fourth Annual Meeting of the American Association of Oral and Maxillofacial Surgeons. Atlanta, Georgia. October 22-25, 1982.
 47. Aldridge KE, Bednar NM, Marier RL, Sanders CV. Comparison of the sensitivity of coagulase-negative staphylococcal species to various antibiotics. Eighty-third Annual

- Meeting of the American Society for Microbiology. New Orleans, Louisiana. March 6-11, 1983.
48. Pepper L, Zide MF, Sanders CV, Marier RL. Intravenous and oral cyclacillin in anaerobic maxillofacial infections. Sixty-fifth Annual Meeting of the American Association of Oral and Maxillofacial Surgeons. Las Vegas, Nevada. 1983.
 49. Sanders CV, Marier RL. Penetration of sulbactam (CP-45, 899) into human cerebrospinal fluid. Thirteenth International Congress of Chemotherapy. Vienna, Austria. August 28-September 2, 1983.
 50. Aldridge KE, Sanders CV, Faro S, Marier RL. Comparison of the in vitro activity of azlocillin and mezlocillin with other antibiotics against clinical isolates of *Bacteroides fragilis*, *B. melaninogenicus*, and *B. bivivus*. Thirteenth International Congress of Chemotherapy. Vienna, Austria. August 28-September 2, 1983.
 51. Marier RL, McCloskey RV, Dickinson G, Sanders CV, Hoffman T, Gutterman D, Aldridge KE. Comparative clinical trial of N-formimidoyl-thienamycin-dehydropeptidase inhibitor (MS0787/0791) and cefalozin. Thirteenth International Congress of Chemotherapy. Vienna, Austria. August 28-September 2, 1983.
 52. Marier RL, Sanders CV, Yu SL, Rounds O, Martin DH, Derks FW, Aldridge KE. Single dose bacampicillin versus multidose amoxicillin therapy or urinary tract infection. International Congress of Antimicrobial Agents and Chemotherapy. Las Vegas, Nevada. October 24-27, 1983.
 53. Marier RL, Sanders CV, Yu SL, Rounds O, Martin DH, Derks FW, Aldridge KE. Single dose bacampicillin versus multidose amoxicillin therapy or urinary tract infection. International Congress of Antimicrobial Agents and Chemotherapy. Las Vegas, Nevada. October 24-27, 1983.
 54. Janney A, Robichaux CJ, Marier RL, Sanders CV. Evaluation of the antimicrobial removal device (ARD) for detection of bacteremia in patients receiving antibiotics. International Congress of Antimicrobial Agents and Chemotherapy. Las Vegas, Nevada. October 24-27, 1983.
 55. Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH. Ticarcillin/clavulanic acid (TIC-CIA) (BRL 28500) in the therapy of serious infections. International Congress of Antimicrobial Agents and Chemotherapy. Las Vegas, Nevada. October 24-27, 1983.
 56. Soto LF, Sanders CV, Marier RL. Acinetobacter community-acquired pneumonia. American College of Physicians Louisiana Chapter Associates Scientific Meeting. New Orleans, Louisiana. November 19, 1983.

57. Aldridge KE, Sanders CV, Martin DH, Marier RL. In vitro comparison of β -lactam antibiotics, alone and in combination with clavulanic acid and sulbactam and effect of inoculum against clinical isolates of bacteria. *Clin Res* 31:879A, 1983.
58. Hanna BJ, Schechter FG, Sanders CV. Infective endocarditis (IE) in the patient over 50. Southern Society for Clinical Investigation. New Orleans, Louisiana. 1984.
59. Aldridge KE, Kogos C, Sanders CV, Marier RL. Comparison of commercial serological kits with the tube coagulase test in the identification of *Staphylococcus aureus*. Eighty-fourth Annual Meeting of the American Society for Microbiology. St. Louis, Missouri. March 4-9, 1984.
60. Aldridge KE, Sanders CV, Marier RL. Synergism and potentiation of ceftaxime by desacetylcefotaxime *in vitro* against strains of *Bacteroides fragilis* group. Eighty-fourth Annual Meeting of the American Society for Microbiology. St. Louis, Missouri. March 4-9, 1984.
61. Aldridge KE, Schiro D, Sanders CV, Marier RL. Ciprofloxacin (BAY09867): comparative activity with beta-lactam antibiotics and gentamicin against aerobic gram positive and negative bacteria. Eighty-fourth Annual Meeting of the American Society for Microbiology. St. Louis, Missouri. March 4-9, 1984.
62. Aldridge KE, Sanders CV, Marier RL. The effect of inoculum on the in vitro activity of beta-lactam antibiotics alone and in combination with clavulanic acid and sulbactam against clinical isolates of bacteria. Charter Conference of the Inter-American Society for Chemotherapy, Inc. St. Petersburg, Florida. December 9-12, 1984.
63. Aldridge KE, Sanders CV, Faro S, Marier RL, Pastorek J. Comparison of the in vitro activity of HR810, a new cephalosporin with other beta-lactam antibiotics against *Streptococcus agalactiae*. Charter Conference of the Inter-American Society for Chemotherapy, Inc. St. Petersburg, Florida. December 9-12, 1984.
64. DeBoisblanc BP, Sanders CV. Actinomycosis: the Charity Hospital experience. American College of Physicians Louisiana Chapter Associates Scientific Meeting. New Orleans, Louisiana. 1984.
65. Derks FW, Sanders CV. Choosing antibiotics for anaerobic infections. Extracta Series, Acron Verlag Publishers. Berlin, Germany. 1984.
66. Aldridge KE, Janney A, Sanders CV. Comparison of the activity of coumermycin, ciprofloxacin, teicoplanin, and other non- β -lactam antibiotics against clinical isolates of methicillin-resistant *Staphylococcus aureus* from various geographical locations. Eighty-fifth Annual Meeting of the American Society for Microbiology. Las Vegas, Nevada. March 3-7, 1985.

67. Aldridge KE, Tsai L, Sanders CV. Comparative activity of ciprofloxacin (BAY o 9867) with beta-lactam antibiotics and gentamicin, and the effect of inoculum size, against aerobic gram positive and negative bacteria. Fourteenth International Congress of Chemotherapy. Kyoto, Japan. June 23-28, 1985.
68. Aldridge KE, Sanders CV. Increased in vitro anti-bacteroides activity of cefotaxime: synergistic interaction of cefotaxime and desacetylcefotaxime. Fourteenth International Congress of Chemotherapy. Kyoto, Japan. June 23-28, 1985.
69. Aldridge KE, Pastorek JG, Faro S, Sanders CV. Significant changes in genital flora in women receiving antibiotic prophylaxis for vaginal hysterectomy: comparison of cefoxitin, mezlocillin, and piperacillin. Annual Meeting of the Infectious Disease Society of Obstetrics-Gynecology. Vancouver, British Columbia. August 1985.
70. Aldridge KE, Janney A, Sanders CV. Carumonam (RO 17-2301), a new monobactam: comparison of in vitro activity with other broad spectrum antibiotics. Twenty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Minneapolis, Minnesota. September 29 – October 2, 1985.
71. Verrette PR, Sanders CV. A brain abscess caused by *Haemophilus aphrophilus*: a case report and review of the literature. American College of Physicians Louisiana Chapter Associates Scientific Meeting. New Orleans, Louisiana. 1985.
72. Aldridge KE, Sanders CV. Carumonam (RO 17-2301), a new monobactam: in vitro synergistic interaction with aminoglycosides against *P. aeruginosa*, *S. marcescens*, *E. cloacae*, and *A. calcoaceticus*. Annual Conference II of the Inter-American Society for Chemotherapy, Inc. Tampa, Florida. December 8-11, 1985.
73. Grandon PW, Sanders CV. Group JK diphtheroid meningitis associated with post-operative CSF leak. American College of Physicians Louisiana Chapter Associates Scientific Meeting. New Orleans, Louisiana. 1985.
74. Aldridge KE, Janney A, Sanders CV. Cefamandole and methicillin-resistant *Staphylococcus aureus*: true or false susceptibility patterns? Eighty-sixth Annual Meeting of the American Society for Microbiology. Washington, D.C. March 23-28, 1986.
75. Aldridge KE, Sanders CV. Pefloxacin, a new fluorinated quinolone antibiotic: comparison of in vitro activity to other broad spectrum antibiotics. International Symposium on New Quinolones. Geneva, Switzerland. July 17-19, 1986.
76. Sanders CV, Aldridge KE. Comparative in vitro activity of ciprofloxacin, norfloxacin, ofloxacin, beta-lactam antibiotics, and gentamicin against aerobic gram positive cocci and gram negative bacilli. International Symposium on New Quinolones. Geneva, Switzerland. July 17-19, 1986.

77. Aldridge KE, Stratton CW, Weeks LP, Sanders CV. Bactericidal activity of cefotaxime (cefotax), cefoxitin (cefox), ceftizoxime (ceftiz), chloramphenicol (chloro), clindamycin (clinda), and metronidazole (metro) using kill-kinetic studies against *Bacteroides fragilis* group (B.F.gr.) isolates. Ninth International Congress of Infectious and Parasitic Diseases. Munich, Germany. July 20-26, 1986.
78. Aldridge KE, Stratton CW, Sanders CV. The role of desacetylcefotaxime (des-cefotax) in the potentiation of cefotaxime (cefotax) against *Bacteroides* species: comparison of in vitro versus in vivo studies. Ninth International Congress of Infectious and Parasitic Diseases. Munich, Germany. July 20-26, 1986.
79. Aldridge KE, Sanders CV. Comparative in vitro activity of ciprofloxacin, ofloxacin and norfloxacin with beta-lactam antibiotics against aerobic gram positive cocci and gram negative bacilli. Ninth International Congress of Infectious and Parasitic Diseases. Munich, Germany. July 20-26, 1986.
80. Aldridge KE, Stratton CW, Weeks LP, Sanders CV. Synergistic bactericidal activity of cefotaxime and desacetyl-cefotaxime in combination versus the antibiotics alone against strains of *Bacteroides fragilis* group. Ninth International Congress of Infectious and Parasitic Diseases. Munich, Germany. July 20-26, 1986.
81. Aldridge KE, Sanders CV. Susceptibility testing of anaerobes: medium-dependent variations in results. Twenty-sixth International Congress on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 1986.
82. Aldridge KE, Sanders CV. Comparison of the in vitro activity of BMY-28100, a new cephalosporin, with other oral antibiotics. Twenty-sixth International Congress on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 1986.
83. Aldridge KE, Sanders CV. Variations in results and interpretation of susceptibilities of *Bacteroides fragilis* group isolates which are methodology dependent. Third Pan American Congress of Infectious Diseases and Chemotherapy. San Juan, Puerto Rico. December 1986.
84. Sanders CV, Besch CL, Zide MF, Marier RL, Aldridge KE, Derks FW. Ampicillin/sulbactam versus clindamycin for maxillofacial infections. Therapeutic Considerations in the Management of Infectious Diseases: Today and Tomorrow. Montreux, Switzerland. July 1987.
85. Fan Y-D, Pastorek JG, Sanders CV. Listeriosis as an obstetric complication in the immunocompromised patient. American College of Obstetrics & Gynecology, District VII Annual Meeting. Little Rock, Arkansas. October 11-15, 1986.
86. Aldridge KE, Valainis G, Sanders CV. Comparison of the activity of ciprofloxacin and 23 other antimicrobial agents against clinical strains of *Chromobacterium violaceum*.

- Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, New York. October 4-7, 1987.
87. Aldridge KE, Wexler HM, Sanders CV, Finegold SM. In vitro antibiograms of *Bacteroides fragilis* group isolates: differences in resistance rates in two institutions due to susceptibility methodology. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, New York. October 4-7, 1987.
 88. Bedsole G, Wallace RJ Jr., Sanders CV, Steele LC, Graham DR. Activity of ciprofloxacin and ofloxacin against *Mycobacterium fortuitum* with emergence of drug resistance during therapy. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, New York. October 4-7, 1987.
 89. Sanders CV. Beta-lactamase inhibitor in the treatment of post C-section endomyometritis. Symposium on Beta-lactamase Inhibition: Therapeutic Implications in Obstetrics and Gynecology. Baylor College of Medicine. Houston, Texas. November 12-15, 1987.
 90. Hoadley DJ, Sanders CV, Schlievert PM. Toxic shock-like syndrome due to *Streptococcus pyogenes* in the setting of soft tissue infection and bacteremia. American Federation for Clinical Research, Southern Section. New Orleans, Louisiana. February 3-5, 1988.
 91. Sanders CV, Besch CL, Zide MF, Marier RL, Aldridge KE, Derks FW. Sulbactam/ampicillin versus clindamycin for maxillofacial infections. American Federation for Clinical Research, Southern Section. New Orleans, Louisiana. February 3-5, 1988.
 92. Sanders CV, Aldridge KE, Yu SL, Derks FW. Trimethoprim/sulfamethoxazole (TMP/SMX) versus cephalosporin in adult women with community-acquired acute pyelonephritis (P). American Federation for Clinical Research, Southern Section. New Orleans, Louisiana. February 3-5, 1988.
 93. Aldridge KE, Wall JH, Facklam R, Reller LB, Janney A, Sanders CV. Identification of viridans streptococci by three commercial systems: comparison with the reference CDC method. Eighty-eighth Annual Meeting of the American Society for Microbiology. Miami Beach, Florida. May 8-13, 1988.
 94. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. Comparison of the in vitro activity of broad-spectrum cephalosporin-cephamycin and penicillin antimicrobial agents against clinical strains of the *Bacteroides fragilis* group: correlation of cross-resistance and B-lactamase production. Eighty-eighth Annual Meeting of the American Society for Microbiology. Miami Beach, Florida. May 8-13, 1988.
 95. Henderberg A, Aldridge KE, Sanders CV. Comparison of the in vitro activity of SC-47111 (NY-198), a new fluoroquinolone, to other antimicrobial agents against staphylococci, streptococci, *Haemophilus influenzae*, and *Branhamella catarrhalis*.

- Eighty-eighth Annual Meeting of the American Society for Microbiology. Miami Beach, Florida. May 8-13, 1988.
96. Aldridge KE, Henderberg A, Sanders CV. SC-47111 (NY-198), a new fluorinated quinolone: comparison of the in vitro activity with other broad-spectrum antimicrobials against *Enterobacteriaceae acinetobacter* and *Pseudomonas aeruginosa*. Sixth Mediterranean Congress of Chemotherapy. Taormina, Sicily, Italy. May 22-27, 1988.
 97. Aldridge KE, Henderberg A, Sanders CV. Lomefloxacin: comparison of the in vitro activity with other broad-spectrum antimicrobials against gram-positive and -negative bacteria. Second International Symposium on New Quinolones. Geneva, Switzerland. August 25-27, 1988.
 98. Aldridge KE, Henderberg A, Sanders CV. Mutational frequency rates of gram-positive and -negative bacteria to lomefloxacin and other quinolones. Second International Symposium on New Quinolones. Geneva, Switzerland. August 25-27, 1988.
 99. Aldridge KE, Henderberg A, Sanders CV, Multicenter Study Group. A multicenter study of resistance and cross-resistant patterns of the *Bacteroides fragilis* group and various species. International Symposium on Anaerobic Bacteria and Bacterial Infections. Monte Carlo, Monaco. September 25-28, 1988.
 100. Aldridge KE, Henderberg A, Sanders CV. In vitro activity of lomefloxacin, a new difluoroquinolone, compared to other broad-spectrum antimicrobials. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California. October 1988.
 101. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. Comparison of resistance and cross-resistance rates of *B. fragilis* group isolates to ceftizoxime, cefoxitin, cefotetan, cefotaxime, ceftriaxone, piperacillin, and clindamycin. Third European Congress on Anaerobic Bacteria and Infections. Munich, Germany. March 1989.
 102. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. Enhanced in vitro activity against *Bacteroides fragilis* species of ticarcillin/clavulanic acid and amoxicillin/clavulanic acid: comparison to the activity of other beta-lactams, clindamycin and metronidazole. Third European Congress on Anaerobic Bacteria and Infections. Munich, Germany. March 1989.
 103. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. In vitro activity of ampicillin and cefoperazone alone and in combination with sulbactam against the *B. fragilis* group, *B. bivivus*, and *B. disiens*. Third European Congress on Anaerobic Bacteria and Infections. Munich, Germany. March 1989.
 104. Henderberg A, Aldridge KE, Sanders CV. The effect of subinhibitory concentrations of lomefloxacin and other quinolones on in vitro resistance levels among clinical strains of

- bacteria. Eighty-ninth Annual Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 1989.
105. Gebbia K, Aldridge KE, Sanders CV. Comparison of the in vitro activity of oral antimicrobials against clinical strains of *Gardnerella vaginalis*. Eighty-ninth Annual Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 1989.
 106. Schiro DD, Aldridge KE, Sanders CV. Disk-elution susceptibility testing of anaerobes: a re-examination of testing parameters. Eighty-ninth Annual Meeting of the American Society for Microbiology. New Orleans, Louisiana. May 1989.
 107. Risi G, Gaumer R, Weeks S, Leete J, Sanders CV. The risk of exposure to human immunodeficiency virus among health care workers (HCW) at a southern U.S. urban hospital. Fifth International Conference on AIDS. Montreal, Canada. June 1989.
 108. Aldridge KE, Gebbia K, Henderberg A, Pastorek J, Sanders CV. In vitro activity of old and new beta-lactams compared to that of clindamycin, doxycycline, and metronidazole against anaerobes isolated from OB-GYN specimens. Annual Meeting of the Infectious Disease Society for Obstetrics-Gynecology. Quebec, Canada. August 1989.
 109. Gorelick K, Jacobs R, Chmel H, Trenholme G, Greenman R, The Xoma Sepsis Study Group (including CV Sanders), Xoma Corp. Efficacy results of a randomized multicenter trial of E5 antiendotoxin monoclonal antibody in patients with suspected gram-negative sepsis. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, Texas. September 17-20, 1989.
 110. Martin MA, Wenzel RP, Gorelick KJ, Xoma Sepsis Study Group, University of Maryland. Prospective national study of gram-negative bacterial (GNB) sepsis—natural history in the 1980s. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, Texas. September 17-20, 1989.
 111. Aldridge KE, Henderberg A, Sanders CV. In vitro activity of beta-lactam/beta-lactamase inhibitor (B-L/B-L-I) combinations against *B. fragilis*, group isolates compared to cefotaxim (FOX) and clindamycin (CLIN). Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy. Houston, Texas. September 17-20, 1989.
 112. Reynaud P, Goodfellow K, Svec F, Sanders CV. Porphyria cutanea tarda as initial presentation in acquired immune deficiency syndrome: two case reports. American Federation for Clinical Research, Southern Section. New Orleans, Louisiana. January 17-19, 1990.
 113. Aldridge KE, Schiro DD, Sanders CV. An in vitro study of the activity of fleroxacin and metronidazole alone and in combination against mono- and polymicrobial inocula. American Society for Microbiology Annual Meeting. Anaheim, California. May 13-17, 1990.

114. Hill MK, Sanders CV. Treatment of the brain abscess. *Ochsner Clinic Reports on Serious Hospital Infections* 5(1):1-8, 1990.
115. MacIntyre NR, Emmanuel G, Wedel NI, Gorelick KJ, Xoma Sepsis Study Group (including CV Sanders). E5 antibody improves outcome from multi-organ failure in survivors of gram-negative sepsis. Society for Critical Care Medicine. Washington, D.C. May 22-26, 1991.
116. Aldridge KE, Pastorek J, Martin D, Sanders CV, Espinosa T. A randomized, blinded comparison of cefotetan and cefoxitin for the treatment of post-Caesarean infection. Annual Meeting of the Infectious Disease Society for Obstetrics-Gynecology. Hamilton, Bermuda. August 1-4, 1991.
117. Sanders CV, Aldridge KE. Treatment of anaerobic infections: 1992. Second International Symposium on Anaerobic Bacteria and Infections. Vienna, Austria. March 3-12, 1992.
118. Sanders CV. Treatment of anaerobic infections with tazobactam/piperacillin. Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies. Prague, Czechoslovakia. August 30 – September 1, 1992.
119. Sanders CV. Piperacillin/tazobactam in the treatment of lower respiratory tract infections. The Sixth European Congress on Intensive Care Medicine 1992. Barcelona, Spain. October 26-31, 1992.
120. Marier RL, Sanders CV, Aldridge KE. Treatment of mixed surgical infections. World Congress of Surgery. Sao Paulo, Brazil.
121. Sanders CV. Role of piperacillin/tazobactam in the treatment of polymicrobial gynecological and skin and skin-structure infections: review of worldwide clinical trials. Eighteenth International Congress of Chemotherapy. Stockholm, Sweden. June 27 – July 2, 1993.
122. Aldridge KE, Schiro DD, Sanders CV. In vitro activity of various β -lactam and β -lactam/ β -lactamase inhibitor combinations against β -lactamase-positive and -negative non-*Bacteroides fragilis* group. Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. October 1993.
123. Aldridge KE, Schiro DD, Sanders CV. Louisiana hot sauce versus *Vibrio* species: never eat oysters without it? Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. October 1993.
124. Aldridge KE, Schiro DD, Sanders CV. Susceptibility of non-*Bacteroides* anaerobes to β -lactam, β -lactam/ β -lactamase inhibitor combinations, and metronidazole. Ninety-fourth

- General Meeting of the American Society for Microbiology. Las Vegas, Nevada. May 23-27, 1994.
125. Aldridge K, Schiro D, Pastorek J, Sanders CV. Comparison of the in vitro susceptibility of anaerobic bacteria associated with female pelvic infection to old and new antimicrobial agents. 1994 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology. Monterey, California. August 3-6, 1994.
 126. Hilton CW, Sanders CV. A relative-value-based system to quantitate faculty performance. American Federation for Clinical Research/Southern Society for Clinical Investigation 1996 Southern Section Meetings. New Orleans, Louisiana. January 31 – February 2, 1996. *J Invest Med* 44:43A, 1996.
 127. Aldridge KE, O’Cain P, Ashcraft D, Sanders CV. Prevalence and distribution of penicillin-resistant *Streptococcus pneumoniae* among strains endemic to Louisiana. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 14-16, 1996.
 128. Aldridge KE, Ashcraft D, O’Cain P, Sanders CV. The prevalence of multiple-antibiotic-resistance among strains of *Streptococcus pneumoniae* with reduced susceptibility to penicillin G. *J Invest Med* 45:13A, 1997.
 129. Fisher WP, Vial RH, Sanders CV. Removing rater effects from medical clerkship evaluations (abstract). *Academic Med* 72:443-444, 1997.
 130. Clark RA, Sanders CV. An update on management of persons with human immunodeficiency virus and acquired immunodeficiency syndrome: introduction to symposium. *Am J Med Sci* 1:1-2, 2004.
 131. Lopez FA, Wilson S, Soileau S, Sanders CV. Update on *vibrio vulnificus* infections in Louisiana: 1977-2002 (abstract). *Southern Med J* 97(10):S22-S23, October 2004 Supplement.
 132. Chauvin SW, Scott JR, Tang T, Sanders CV, Lopez FA, Culotta R, Jain N, Daberkow DW, Figueroa JE, Wiggins GS. A Department of Medicine Model for Educational Development (abstract). Research Day 2005. Louisiana State University – New Orleans School of Medicine, Department of Medicine. February 18, 2005.

Original Articles

1. Burda CD, Sanders CV. Chronic post-rheumatic fever (Jaccoud’s) arthritis. *Arch Intern Med* 120:212-216, 1967.
2. Sanders CV, Hahn R. Analysis of 106 cases of tularemia. *J La State Med Soc* 120:391-393, 1968.

3. Luby JP, Sanders CV. Green monkey disease ("Marburg virus" disease): a new zoonosis. *Am Intern Med* 71:657-659, 1969.
4. Sanders CV, Luby JP, Johanson WG, Barnett JA, Sanford JP, Pierce AK. *Serratia marcescens* infections from inhalation therapy medications: nosocomial outbreak. *Ann Intern Med* 73:15-21, 1970.
5. Luby JP, Sanders CV, Sulkin SE. Interferon assays and quantitative virus determinations in a fatal infection in man with western equine encephalomyelitis virus. *Am J Trop Med Hygiene* 60:765-769, 1971.
6. Allison FA Jr., Sanders CV. The extragenital manifestations of gonococcal infection. *South Med Bull*, 59:38-44, 1971.
7. Sanders CV, Luby JP, Sanford JP, Hull AR. Suppression of interferon response in lymphocytes from patients with uremia. *J Lab Clin Med* 77:768-776, 1971.
8. Hargrove MD, Sanders CV. Extreme elevation in total serum bilirubin: a study of the causes in 32 consecutive cases. *South Med J* 64:213-217, 1971.
9. Luby JP, Sanders CV, Johanson WG, McCubbin JH, Barnett JA, Sanford JP. Trinity serologic survey: a survey of residents of communities along the course of the Trinity River between Houston and Dallas, Texas, for antibodies to the viruses of St. Louis encephalitis, western equine encephalitis and California encephalitis. *Am J Epidemiol* 94:479-486, 1971.
10. Gilbert DN, Sanford JP, Kutscher E, Sanders CV, Luby JP, Barnett JA. Microbiologic study of wound infections in tornado casualties. *Arch Environ Health* 26:125-130, 1973.
11. Glancy DL, Sanders CV, Porta A. Posterior chest wall pulsation in congenital complete absence of the left pericardium. *Chest* 65:564-566, 1974.
12. Sanders CV. Prescribing for upper respiratory infections. Monograph prepared for patient-care projects. 1976.
13. Sanders CV, Saenz RE, Lopez M. Splinter hemorrhages and onycholysis: unusual reactions associated with tetracycline hydrochloride therapy. *South Med J* 69:1090-1092, 1976.
14. Brown JW, Nadell J, Sanders CV, Sardenga L. Brain abscess caused by *Cladosporium trichoides* (*bantianum*): a case with paranasal sinus involvement. *South Med J* 69:1519-1521, 1976.
15. Repath F, Seabury JH, Sanders CV, Domer J. Prosthetic valve endocarditis due to *Mycobacterium chelonae*. *South Med J* 69:222-224, 1976.

16. Mackowiak PA, Sanders CV, Thomason J. Acute meningococemia without meningitis in association with influenza-like illness. *South Med J* 69:222-224, 1976.
17. Bracis R, Sanders CV, Gilbert DN. Methicillin hemorrhagic cystitis. *Antimicrob Agents Chemother* 12:438-439, 1977.
18. Torres JR, Sands M, Sanders CV. In vitro sensitivity of *Mycobacterium marinum* to monocycline and doxycycline. *Tubercle* 59:193-195, 1978.
19. Greenberg RN, Brooks BJ, Sanders CV. The isolated case of Legionnaires' disease. *South Med J* 71:1141-1144, 1978.
20. Torres JR, Sanders CV, Strub RL, Black W. Cat-scratch disease causing reversible encephalopathy. *JAMA* 240:1628-1629, 1978.
21. Greenberg RN, Eversmeter WH, Sanders CV. Hepatitis B presenting with tenosynovitis. *South Med J* 72:375-376, 1979.
22. Greenberg RN, Scalcini MC, Sanders CV, Lewis AC. Cefmandole therapy in anaerobic infections. *Antimicrob Agents Chemother* 15:337-341, 1979.
23. Bryan CS, Huffman LJ, Del Bene VE, Sanders CV, Scalcini MC. Intravenous metronidazole therapy for *Bacteroides fragilis* meningitis. *South Med J* 72:494-497, 1979.
24. Greenberg RN, Sanders CV. Typhoid fever: a public health concern. *JCE Clin Med* 25:16-22, 1979.
25. Klein RC, Sanders CV, Cook EW. Anaerobic lung infections. *JCE Clin Med* 25:24-31, 1979.
26. Torres-R JR, Maki NJ, Taddonio RF, Sanders CV. Cutaneous rhizopus infection associated with elastoplast wound dressing. *Orthopedics* 2:384-386, 1979.
27. Sanders CV, Hanna BJ, Lewis AC. Metronidazole in the treatment of anaerobic infections. *Am Rev Resp Dis* 120:337-343, 1979.
28. Torres-R JR, Taddonio RF, Sanders CV. Spondylitis caused by *Brucella abortus*. *South Med J* 72:1166-1169, 1979.
29. Torres-R JR, Sanders CV, Lewis AC. Vancomycin concentration in human tissues—preliminary report. *J Antimicrob Chemother* 5:475-477, 1979.
30. Greenberg RN, James RB, Marier RL, Wood WH, Sanders CV, Kent JN. Microbiologic and antibiotic aspects of infections in the oral and maxillofacial region. *J Oral Surg* 37:873-884, 1979.

31. Sanders CV, Hanna BJ, Lewis AC, Scalcini M. The use of metronidazole in the treatment of anaerobic pleuropulmonary infections. *Proceedings of the Second International Symposium on Anaerobic Infections*. Geneva, Switzerland. April 25-27, 1979. International Congress and Symposium Series, No. 18. The Royal Society of Medicine, New York, Grune & Stratton, 1979.
32. Sanders CV, Bourge RC. When and how to use the new cephalosporins. *Contemp Ob Gyn* 14:67-77, 1979.
33. Torres-R JR, Sanders CV. Guidelines for using aminoglycosides. *Contemp Ob Gyn* 14:39-47, 1979.
34. Scalcini MC, Sanders CV. Endocarditis from human-to-human transmission of *Staphylococcus aureus*. *Arch Intern Med* 140:111-112, 1980.
35. Sanders CV. Treating anaerobic infection in the 1980s. *Contemp Ob Gyn* 15:69-89, 1980.
36. Sanders CV. The aminoglycosides: an overview. *Syva Monitor*, No. 6, pp 1-8, May 1980.
37. Greenberg RN, Scalcini MC, Sanders CV, Lewis AC. The treatment of serious anaerobic infections. *Scan J Infect Dis*, Suppl 25:84-88, 1980.
38. Torres-R JR, Sanders CV, Swenson RM, Hanna B, Lorber B, Lewis AC. Treatment of anaerobic infections with ticarcillin: clinical and laboratory results. *Curr Ther Res* 30:528-534, 1981.
39. Greenberg RN, Sanders CV, Lewis AC, Marier RL. Single dose cefaclor therapy of urinary tract infection: evaluation of antibody coated bacteria tested and C-reactive protein assay as predictors of cure. *Am J Med* 71:841-845, 1981.
40. Torres-R JR, Stratton CW, Sanders CV, et al. Candidal suppurative peripheral thrombophlebitis. *Ann Intern Med* 96:431-435, 1982.
41. Martin DH, Sanders CV, Marier RL. N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria. *Antimicrob Agents Chemother* 21:168-169, 1982.
42. Derks FW, Sanders CV, Marier RL. Choosing initial antimicrobial therapy. *Consultant* 22:117-129, 1982.
43. Marier RL, Marinaccio AT, Sanders CV, Aldridge KE, Mitchell JW. Susceptibility patterns of bacteria following therapy with piperacillin. *J Antimicrob Chemother* 9 (Suppl B):85-91, 1982.

44. Marier RL, Aldridge KE, Sanders CV. The role of anaerobes in sinus and middle ear infections—implications for the future. *Proceedings of the First United States Metronidazole Conference*, S Finegold (ed), pp 345-356, Biomedical Information Corporation, 1982.
45. Sanders CV, Aldridge KE, Marier RL. Diagnosis of anaerobic infections. *Proceedings of the First United States Metronidazole Conference*, S Finegold (ed), pp 11-23, Biomedical Information Corporation, 1982.
46. Marier RL, Faro S, Sanders CV, Williams WL, Derks FW, Janney A, Aldridge KE. Moxalactam in the therapy of serious infections. *Antimicrob Agents Chemother* 21:650-654, 1982.
47. Marier RL, Sanders CV, Faro S, Janney A, Williams WL, Derks FW, Aldridge KE. Piperacillin versus carbenicillin in the therapy for serious infections. *Arch Intern Med* 142:2000-2005, 1982.
48. Korzeniowski OM, Sande MA, National Collaborative Endocarditis Study Group (including CV Sanders). Combination antimicrobial therapy of *Staphylococcus aureus* endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. *Ann Intern Med* 97:496-503, 1982.
49. Faro S, Sanders CV, Aldridge KE. Use of single agent antimicrobial therapy in the treatment of polymicrobial female pelvic infections. *Obstet Gynecol* 60:232-236, 1982.
50. Brooks BJ Jr., Marier R, Sanders CV. Ulcer of the hard palate. *JAMA* 247:819-820, 1982.
51. Franklin RM, Bond W, Sanders CV, Joffe L. Presumed blastomycosis endophthalmitis. *Ann Ophthalmol* 14:1183-1188, 1982.
52. Jain A, Sanders CV, Nicholle FI. Drug fever during treatment of pulmonary edema. *South Med J* 75:1140-1141, 1982.
53. Brooks BJ, Williams WL, Sanders CV, Marier RL. Apparent ketoconazole failure in candidal cholecystitis. *Arch Intern Med* 142:1934-1935, 1982.
54. Aldridge KE, Sanders CV, Lewis AC, Marier RL. Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production. *J Med Microbiol* 16:75-82, 1983.
55. Chambers HF, Korzeniowski OM, Sande MA, National Collaborative Endocarditis Study Group (including CV Sanders). *Staphylococcus aureus* endocarditis: clinical manifestations in addicts and nonaddicts. *Medicine* 62:170-177, 1983.
56. Wickboldt LG, Sanders CV. *Vibrio vulnificus* infection: case report and update since 1970. *J Am Acad Dermatol* 9:243-251, 1983.

57. Sanders CV, Aldridge KE. The microbiology lab: garbage in, garbage out. *Clin Micro Newsletter* V5(18), September 15, 1983.
58. Bordelon JY, Legrand P, Gewin WC, Sanders CV, Marier RL. Interlaboratory variation of antibiograms of methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* strains with conventional and commercial testing systems. *J Clin Micro* 18:1226-1236, 1983.
60. Sanders CV. Anaerobic infections. *Turning Points in Infection*, No. 3. Lederle Laboratories: Wayne, New Jersey, 1983.
61. Marier RL, McCloskey RV, Dickenson G, Sanders CV, Aldridge KE, Hoffman T, Gutterman D, Janney A. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. *J Antimicrob Chemother* 12 (Suppl D): 133-139, 1983.
62. Karam GH, Sanders CV. Acute sinusitis. Dial Access Program. Southern Medical Association, 1984.
63. Karam GH, Sanders CV. Subacute and chronic sinusitis. Dial Access Program. Southern Medical Association, 1984.
64. Derks FW, Sanders CV, Marier RL. Anaerobic infections: a guideline for choosing antibiotics. *Consultant*, January:206-226, 1984.
65. Aldridge KE, Kogos C, Sanders CV, Marier RL. Comparison of rapid identification assays for *Staphylococcus aureus*. *J Clin Microbiol* 19:703-704, 1984.
66. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of *Bacteroides*. *Diag Microbiol Inf Dis* 2:47S-53S, 1984.
67. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL. Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of *Bacteroides* species. *Antimicrob Agents Chemother* 26:410-413, 1984.
68. Sanders CV, Greenberg RN, Marier RL. Cefamandole and cefotoxin. *Ann Intern Med* 103:70-78, 1985.
69. Aldridge KE, Schiro D, Tsai L, Janney A, Sanders CV, Marier RL. Ciprofloxacin (Bay o 9867): an in vitro comparison with other broad spectrum antibiotics. *Curr Ther Res* 37:754-762, 1985.

70. Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH. The safety and effectiveness of ticarcillin/clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women. *Am J Med* 79 (Suppl 5B):96-100, 1985.
71. Aldridge KE, Janney A, Sanders CV. Comparison of the activity of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant *Staphylococcus aureus* from various geographical locations. *Antimicrob Agents Chemother* 28:634-638, 1985.
72. Kumar P, Bentley FR, Leech SH, Sanders CV. Accidental administration of hepatitis B immune globulin to a patient positive for hepatitis B surface antigen. *Ann Allergy* 55:683-685, 1985.
73. Aldridge KE, Tsai L, Sanders CV. Comparative activity of ciprofloxacin (BAY o 9867) with beta-lactam antibiotics and gentamicin, and the effect of inoculum size, against aerobic gram-positive and -negative bacteria. *Recent Advances in Chemotherapy: Antimicrobial Section*, University of Tokyo Press, pp 606-607. Proceedings of the 14th International Congress of Chemotherapy: Kyoto, Japan, June 23-28, 1985.
74. Aldridge KE, Sanders CV. Increased in vitro anti-*Bacteroides* activity of cefotaxime: synergistic interaction of cefotaxime and desacetylcefotaxime. *Recent Advances in Chemotherapy: Antimicrobial Section*, University of Tokyo Press, pp 606-607. Proceedings of the 14th International Congress of Chemotherapy: Kyoto, Japan, June 23-28, 1985.
75. Besch CL, Sanders CV. Managing sepsis—a common cause of geriatric death. *Geriatrics* 41:55-66, 1986.
76. Aldridge KE, Sanders CV, Marier RL. Variation in the potentiation of β -lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria. *Antimicrob Agents Chemother* 17:463-469, 1986.
77. Zide MF, Sanders CV, Marier RL, Aldridge KE, Derks FW. Cefuroxime therapy for maxillofacial infections. *Curr Ther Res* 40:278-287, 1986.
78. Aldridge KE, Sanders CV. Comparison of the activity of carumonam (RO 17-2301) with other broad-spectrum antibiotics: in vitro antibacterial spectrum, inoculum effect, and synergy studies. *Curr Ther Res* 40:515-527, 1986.
79. Aldridge KE, Sanders CV. Comparison of the activity of cefpirome (HR 810), a new cephalosporin, to other beta-lactam against clinical isolates of *Streptococcal agalactiae*. *Curr Ther Res* 40:1069-1077, 1986.
80. Aldridge KE, Schiro DD, Sanders CV. Pefloxacin (RB 1589): an in vitro comparison with other oral antimicrobial agents and imipenem. *Curr Ther Res* 40:1103-1113, 1986.

81. Besch CL, Sanders CV. Managing sepsis—a common cause of geriatric death. *Geriat Dig* 8:29-30, 1986.
82. Sanders CV, Derks FW. Drugs as a cause of unexplained fever. *Modern Med* 55:72-77, 1987.
83. Aldridge KE, Schiro DD, Sanders CV. RO 23-6240, a new absorbed quinolone: in vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem. *Diag Microbiol Infect Dis* 7:9-19, 1987.
84. Saenz C, Sanders CV, Nguyen BP, Reisin E. Macronodular lesions associated with *Staphylococcal aureus* bacteremia: a condition that resembles a “lymphocutaneous” syndrome. *Arch Intern Med* 147:793, 1987.
85. Aldridge KE, Schiro DD, Sanders CV. Comparative in vitro activity of new oral cephalosporin BMY-28100. *Eur J Clin Microbiol* 6:170-172, 1987.
86. Aldridge KE, Schiro DD, Sanders CV. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074. *Eur J Clin Microbiol* 6:564-569, 1987.
87. Aldridge KE, Sanders CV. Antibiotic- and method-dependent variation in susceptibility testing results of *Bacteroides fragilis* group isolates. *J Clin Microbiol* 25:2317-2321, 1987.
88. Sanders CV. Comparative in vitro activity of ciprofloxacin, norfloxacin, ofloxacin, β -lactam antibiotics, and gentamicin against aerobic gram-positive cocci and gram-negative bacilli. *Rev Infect Dis* 10(S1):S42, 1987.
89. Sanders CV. Role of newer antimicrobials in the treatment of mixed aerobic/anaerobic infections (monograph). *Therapeutic Advances in the Treatment of Infectious Diseases*. Pragmaton Publications: Chicago, Illinois, 1987.
90. Hill MK, Sanders CV. Localized and systemic infections due to *vibrio* species. *Inf Dis Clin NA* 1:687-707, 1987.
91. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Methylprednisolone Severe Sepsis Study Group (including CV Sanders). Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. *Chest* 92:1032-1036, 1987.
92. Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA, Methylprednisolone Severe Sepsis Study Group (including CV Sanders). A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med* 317:653-658, 1987.

93. Bartlett JG, Ledger WJ, Sanders CV. A site-by-site attack on anaerobes. *Patient Care*. March 30, 1987.
94. Aldridge KE, Sanders CV. Pefloxacin, a new fluorinated quinolone: comparison of its in vitro activity with that of other broad-spectrum antibiotics. *Rev Infect Dis* 10(S1):S40-S41, 1988.
95. Hill MK, Sanders CV. Principles of antimicrobial therapy for head and neck infections. *Inf Dis Clin NA* 2:57-83, 1988.
96. Sanders CV, Pastorek JG, Miller JM, Aldridge KE. Ticarcillin disodium and clavulanate potassium in the treatment of post-Cesarean-section endomyometritis. *J Reprod Med* 33 (Suppl):584-587, 1988.
97. Dudley MN, Neu HC, Pankey GA, Sanders CV, Sweet RL. Roundtable discussion: use of β -lactamase inhibitors in antibiotic therapy: AP&T Committee review of ampicillin/sulbactam. *Hosp Formul* 23 (Suppl A):9-14, 1988.
98. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. Susceptibility of *Bacteroides fragilis* group isolates to broad spectrum beta-lactams clindamycin and metronidazole: rates of resistance, cross-resistance, and importance of beta-lactamase production. *Advan Ther* 5:273-282, 1988.
99. Aldridge KE, Valainis GT, Sanders CV. Comparison of the in vitro activity of ciprofloxacin and 24 other antimicrobial agents against clinical strains of *Chromobacterium violaceum*. *Diag Microbiol Inf Dis* 10:31-39, 1988.
100. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, Methylprednisolone Severe Sepsis Study Group (including CV Sanders). The sepsis syndrome: a valid clinical entity. *Crit Care Med* 17:389-393, 1989.
101. Aldridge KE, Weeks LS, Stratton CW, Sanders CV. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against *Bacteroides fragilis* group organisms. *Diag Microbiol Inf Dis* 12:165-170, 1989.
102. Aldridge KE, Henderberg A, Sanders CV. Lomefloxacin, a new fluoroquinolone: studies on in vitro antimicrobial spectrum, potency, and development of resistance. *Diag Microbiol Inf Dis* 12:221-233, 1989.
103. Champagne KJ, Sanders CV, Hastings PR. *Aeromonas hydrophilia* in water and soil contaminated injuries. *Infect Med* Jan/Feb:19-25, 1989.
104. Fan Y-D, Pastorek JG, Janney FA, Sanders CV. Listeriosis as an obstetric complication in an immunocompromised patient. *South Med J* 82:1044-1045, 1989.

105. Risi GF, Gaumer R, Weeks S, Leete J, Sanders CV. Human immunodeficiency virus: risk of exposure among health care workers at a southern US urban hospital. *South Med J* 82:1079-1082, 1989.
106. Aldridge KE, Henderberg A, Sanders CV. Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against *Enterobacteriaceae*, *Acinetobacter* spp, *Aeromonas* spp, and *Pseudomonas aeruginosa*. *Diag Microbiol Infect Dis* 12:1S-6S, 1989.
107. Aldridge KE, Henderberg A, Gebbia K, Schiro DD, Janney A, Sanders CV. Lomefloxacin, a new fluoroquinolone: studies on in vitro antimicrobial spectrum, potency, and development of resistance. *Diag Microbiol Infect Dis* 12:221-233, 1989.
108. Champagne KJ, Sanders CV, Hastings PR. *Aeromonas hydrophilia* in water and soil contaminated injuries. *Infections in Surgery: Epidemiology of Inf* April:139-142, 1989.
109. Aldridge KE, Henderberg A, Sanders CV. Mutational frequency of gram-positive and gram-negative bacteria to resistance to lomefloxacin and other quinolones. *Rev Infect Dis* 11 (Suppl 5):S974-S975, 1989.
110. Risi GF, Sanders CV. The genital mycoplasmas. *Obstet Gynecol Clin NA* 16:611-626, 1989.
111. Aldridge KE, Henderberg A, Sanders CV. In vitro activity of lomefloxacin against gram-positive and gram-negative bacteria. *Rev Infect Dis* 11:S935, 1989.
112. Wallace RJ Jr., Bedsole G, Sumpter G, Sanders CV, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. *Antimicrob Agents Chemother* 34:65-70, 1990.
113. Aldridge KE, Wexler HM, Sanders CV, Finegold SM. Comparison of in vitro antibiograms of *Bacteroides fragilis* group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology. *Antimicrob Agents Chemother* 34:179-181, 1990.
114. Aldridge KE, Henderberg A, Sanders CV. Susceptibility of cefoxitin-resistant *Bacteroides fragilis* group strains to other beta-lactam and non-beta-lactam antimicrobials. *Advan Ther* 7:16-21, 1990.
115. Aldridge KE, Henderberg A, Schiro DD, Sanders CV. Discordant results between the broth disk elution and broth microdilution susceptibility tests with *Bacteroides fragilis* group isolates. *J Clin Micro* 28:375-378, 1990.
116. Sanders CV, Aldridge KE. In vitro anaerobic data on ticarcillin/clavulanate: a review of an ongoing survey. *J Reprod Med* 35:313-316, 1990.

117. Aldridge KE, Henderberg A, Sanders CV. In vitro study of the susceptibility of cefoxitin/cefotetan resistance *Bacteroides fragilis* group strains to various other antimicrobial agents. *J Antimicrob Chemother* 26:353-359, 1990.
118. Aldridge KE, Weeks LS, Stratton CW, Sanders CV. Differences in the in vitro inhibitory and bactericidal activity of ceftizoxime, cefoxitin, cefotetan, and penicillin G against *Bacteroides fragilis* group isolates: comparison of time-kill kinetic studies with MIC values. *Diag Microbiol Infect Dis* 13:311-316, 1990.
119. Aldridge KE, Wexler HM, Sanders CV, Finegold SM. Comparison of in vitro antibiograms of *Bacteroides fragilis* group isolates: differences in resistance rates in two institutions because of differences in susceptibility methodology. *Antimicrob Agents Chemother* 34:179-181, 1990.
120. Greenman RL, Schein RMH, Martin MA, et al, and the Xoma Sepsis Study Group (including CV Sanders). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. *JAMA* 266:1097-1102, 1991.
121. Hill MK, Sanders CV. Tuberculosis in pregnancy. *Contemp OB/GYN* 36:104-110, 1991.
122. Pastorek JG II, Sanders CV. Antibiotic therapy for post-Caesarean endomyometritis. *Rev Infect Dis* 13:S752-S757, 1991.
123. Sanders CV, Aldridge KE. Antimicrobial therapy of anaerobic infections—1991. *Pharmacother* II:72S-79S, 1991.
124. Karam GH, Sanders CV, Aldridge KE. Role of newer antimicrobial agents in the treatment of mixed aerobic and anaerobic infections. *Surg Gynecol Obstet* 172 (Suppl):57-64, 1991.
125. Hill MK, Sanders CV. Anaerobic disease of the lung. *Infect Dis Clin NA* 5:453-466, 1991.
126. Rodriguez MC, Musher DM, Hamill RJ, Dowell M, Bagwell JT, Sanders CV. Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited. *CID* 14:192-199, 1992.
127. Sanders CV, Aldridge KE. Current antimicrobial therapy of anaerobic infections. *Eur J Clin Microbiol & Infect Dis* 11:999-1011, 1992.
128. Hill MK, Sanders CV. Tuberculosis and pregnancy. In: Mead PB, Hager WD, Faro S, eds. *Infection Protocols for Obstetrics and Gynecology*, 2nd ed. Montvale, NJ: Medical Economics. 1992.

129. Marier RL, Sanders CV, Aldridge KE. Treatment of polymicrobial infections. *Proceedings of an International Conference: Advances in Beta-Lactamase-Inhibitor Combination Therapy: A Perspective in Piperacillin/Tazobactam in Surgery*. São Paulo, Brazil. *Complications in Surgery* 12 (Suppl A):70-76, 1993.
130. Sanders CV, Hill MK. *Vibrio vulnificus*. *Infect Dis Prac* 17:1-4, May 1993.
131. Aldridge KE, Gelfand M, Reller LB, Ayers LW, Pierson CL, Schoenknecht F, Tilton RC, Wilkins J, Henderberg A, Schiro D, Johnson M, Janney A, Sanders CV. A five-year multicenter study of the susceptibility of the *B. fragilis* group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States. *Diag Microbiol Infect Dis* 18:235-241, 1994.
132. Sanders CV. Respiratory RX: new broad spectrum agent addresses beta-lactam resistance. *Advance Managers Resp Care* 3:39-40, Mar 1994.
133. Sanders CV Jr. Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review. *Intens Care Med* 2:S21-S26, 1994.
134. Hill MK, Sanders CV. Polymicrobial infections. *Ochsner Clinic Reports on Serious Hospital Infections* 6:1-8, 1994.
135. Sanders CV. Treatment of polymicrobial gynecologic and skin and skin-structure infections: worldwide clinical trials. Piperacillin/Tazobactam: A New Dimension in Antibiotic Therapy. *Infect Dis Clin Prac* 4:S26-32, 1995.
136. Hill MK, Sanders CV. Community-acquired pneumonia. *Ochsner Clinic Reports on Serious Hospital Infections* 7:1-8, 1995.
137. Hill MK, Sanders CV. Leptospirosis pneumonia. *Seminars in Respiratory Infections* 12:44-49, 1997.
138. Hilton CH, Fisher WP, Lopez-S A, Sanders CV. A relative-value-based system for quantification of faculty productivity: a simple, adjustable, weighted system for calculating faculty productivity in teaching, research, administration, and patient care. *Academic Med* 72:787-793, 1997.
139. Aldridge KE, Ashcraft DS, Sanders CV. RP 59,500 (Quinupristin/Dalfopristin): a new streptogramin with potent activity against penicillin-resistant *Streptococcus pneumoniae*. *Adv in Therapy* 15(3):158-164, May/June 1998.
140. Sanders CV. Introduction. *Rheumatic Disease Clinics of North America: Infectious Arthritis* 24(2):xiii-xiv. May 1998. LR Espinoza, ed. Philadelphia: W.B. Saunders.

141. Hill MK, Sanders CV. Skin and soft tissue infections in critical care. *Critical Care Clinics: Infections in Critical Care II* 14(2):251-262. April 1998. B.A. Cunha, ed. Philadelphia: W.B. Saunders.
142. Aldridge KE, Ashcraft D, Sanders CV. Trovafloxacin (CP 99,219), a new azabicyclopenthyridone antimicrobial: inhibitory and bactericidal activity against clinical isolates of penicillin-susceptible and -resistant *Streptococcus pneumoniae*. *Adv in Ther* 15:65-74, 1998.
143. Clark R, Martin DH, Hilton C, Sanders CV. The impact of human immunodeficiency virus disease on academic health centers. *APM* 105:87-90. Aug 1998.
144. Aldridge KE, Ashcraft DS, O'Cain P, Sanders CV, Janney A, Brown W, Silberman R, Pankey G. A multicenter study of the prevalence and susceptibility patterns of isolates of *Streptococcus pneumoniae* with reduced susceptibility to penicillin G in Louisiana. *Amer J Med Sci* 316(4):277-284. Oct 1998.
145. Sanders CV. Community-acquired pneumonia: triage in the emergency room. *J Resp Dis* 19(Suppl 10A): S27-32. Oct 1998.
146. Saenz RE, Sanders CV, Aldridge KE, Patel MM. Purulent pericarditis with cardiac tamponade caused by *Streptococcus pneumoniae* highly resistant to penicillin, cefotaxime, and ceftriaxone. *Clin Infect Dis* 26:762-763. Mar 1998.
147. Mendez EA, Espinoza LM, Harris M, Angulo J, Sanders CV, Espinoza LR. Systemic lupus erythematosus complicated by necrotizing fasciitis. *Lupus*. Feb 1999.
148. Taylor S, Sanders CV. Unusual manifestations of pneumococcal infection. *Am J of Med* 107(1A):12S-27S. Jul 1999.
149. Butt AA, Lopez FA, Sanders CV. Treatment of non-tuberculous mycobacteria. *Antibiotics for Clinicians* 4(2):26-30. Mar/Apr 2000.
150. Hamade S, Sanders CV, Hyslop NE. Hemoptysis following a chronic illness. In: Steele, Russel, MD, eds. *Infect in Med* 17(7):476-487. Jul 2000.
151. Saenz RE, Brown WD, Sanders CV. Allergic bronchopulmonary disease caused by *Bipolaris hawaiiensis* presenting as a necrotizing pneumonia: case report and review of literature. *Am J Med Sci* 1(3):209-212, Oct 2000.
152. Slaven EM, Lopez FA, Hart SM, Sanders CV. Myonecrosis caused by *Edwardsiella tarda*: a case report and case series of extraintestinal *E. tarda* infections. *Clin Infect Dis* 32(10):1430-1433, May 2001.
153. Lopez FA, Sanders CV. Dermatologic infections (non HIV) in the immunocompromised host. *Infect Dis Clin North Am* 15(2):671-702, xi. Jun 2001.

154. Lillis RA, Dugan V, Mills T, Berner A, Sanders CV, Hagensee M, Lopez FA. A fish hook and liver disease: revisiting an old enemy. *J La State Med Soc* 154:20-25, Jan/Feb 2002.
155. Lopez FA, Sanders CV. Recognizing cutaneous signs of infection in immunocompromised patients: what to expect in the non-HIV setting. *J Crit Ill* 17:11, Nov 2002.
156. Aldridge KE, Sanders CV. Susceptibility trending of blood isolates of the *Bacteroides fragilis* group over a 12-year period to clindamycin, ampicillin-sulbactam, cefoxitin, imipenem, and metronidazole. *Anaerobe* 8:301-305, 2002.
157. Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to *Bacteroides fragilis* group: distribution of species, β -lactamase production, and antimicrobial susceptibility patterns. *Antimicrobial Agents and Chemotherapy*, Jan 2003, 148-153.
158. Lopez FA, Sanders CV. Abstracts & analysis: cutaneous infection by *Fusarium* species in healthy and immunocompromised hosts: implications for diagnosis and management [Perspectives]. *MD Consult Infectious Disease*. March 6, 2003. Available at <http://www.mdconsult.com>.
159. Lopez FA, Sanders CV. Recognizing cutaneous signs of infection in immunocompromised patients. *Abstracts in Hem/Onc*. Summer 2003, 19-26.
160. Kruspe R, Lillis R, Daberkow DW, Blais CM, Wilbright W, Gupta S, Gould CA, Sun T, Martinez JA, deBoisblanc B, Ladabaum U, Sanders CV, Lopez FA. Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia. *J La State Med Soc*, Nov/Dec 2003, 325-331.
161. Butt AA, Aldridge KE, Sanders CV. Infections related to the ingestion of seafood. Part I: viral and bacterial infections. *Lancet*, 4:201-212, 2004.
162. Kruspe R, Lillis R, Daberkow DW, Blais CM, Wilbright W, Gupta S, Gould CA, Sun T, Martinez JA, deBoisblanc B, Ladabaum U, Sanders CV, Lopez FA. Increasing pneumococcal polysaccharide vaccine rates in hospitalized patients: the LSU-New Orleans Internal Medicine House-staff Initiative for Performance Improvement (HIPI) experience. *Louisiana Morbidity Report* 15:2, Mar/Apr 2004.
163. Butt AA, Aldridge KE, Sanders CV. Infections related to the ingestion of seafood. Part II: parasitic infections and food safety. *Lancet*, 4:294-300, 2004.
164. Sanders CV. Hurricane Katrina and the LSU-New Orleans Department of Medicine: Impact and lessons learned. *AJMS*, 332(5):283-288, 2006.

Book Chapters

1. Sanders CV. Diagnostic virology. In: *Human Diseases Caused by Viruses: Recent Developments*. Rothschild H, Allison R Jr., Howe C, eds. New York, NY: Oxford University Press, 1978.
2. Buechner HA, Sanders CV. Preparation of texts for plates on actinomycosis, nocardiosis, histoplasmosis, North American blastomycosis, South American blastomycosis, coccidioidomycosis, cryptococcosis, and hypersensitivity pneumonitis due to the inhalation of organic dust. In: *The Civa Collection of Medical Illustrations: Respiratory System*. Netter FH, ed. Vol. 7. Summitt, NJ: Ciba, 1979. 190-198, 216-218.
3. Sanders CV, Torres-R JR. Rational use of the diagnostic virology laboratory. In: *Infectious Diseases: Current Topics*. Gilbert DN, Sanford JP, eds. New York, NY: Grune & Stratton, 1979. 107-121.
4. Sanders CV. Tularemia. In: *Tice's Practice of Medicine*. Vol. 3. Hagerstown, MD: Harper & Row, 1970. 1-13. Reprinted in Spittel JA Jr., ed. *Clinical Medicine*, 1980.
5. Sanders CV, Lewis AC. Changing trends in the antimicrobial susceptibility pattern of anaerobic bacteria. In: *Anaerobic Bacteria: Selected Topics*. Lambe DW Jr., Genco RJ, Mayberry-Carson KJ, eds. New York, NY: Plenum, 1981.
6. Sanders CV, Torres-R JR. Tularemia. In: *Infectious Diseases*. Sanford JP, Luby JP, eds. New York, NY: Grune & Stratton, 1981. 265-268.
7. Sanders CV, Torres-R JR. Infections due to other pasteuriae and Yersinia. In: *Infectious Diseases*. Sanford JP, Luby JP, eds. New York, NY: Grune & Stratton, 1981. 268-270.
8. Marier RL, Sanders CV. Infectious diseases. In: *Family Medicine Principles and Practice*. Taylor RB, ed. 2nd ed. New York, NY: Springer-Verlag, 1982.
9. Derks FW, Williams WL, Sanders CV, Marier RL. Infectious diseases of the nervous system. In: *Essentials of Clinical Neurology*. Weisberg LA, Strub RL, Garcia CA, eds. Baltimore, MD: University Park Press, 1983. 305-324.
10. Sanders CV, Greenberg RN. Ear, nose, and throat infections. In: *Clinical Manual of Infectious Diseases*. Rytel MW, MogabgabWJ, eds. Chicago, IL: Yearbook Medical Publishers, 1984. 62-76.
11. Aldridge KE, Sanders CV, Janney A, Faro S, Marier RL. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of

- Bacteroides*. In: *New Concepts of Antimicrobial Interactions with Drug Metabolites and Blood Elements*. Jones RN, ed. Amsterdam, The Netherlands: Excerpta Medica, 1984. 15-17.
12. Derks FW, Sanders CV. Rickettsial diseases. In: *Current Diagnosis*. Conn RB, ed. 7th ed. Philadelphia, PA: WB Saunders Company, 1985. 218-224.
 13. Risi GF, Sanders CV. Anaerobic infections of the urinary tract. In: *Anaerobic Infections in Humans*. Finegold SM, George WL, eds. Florida: Academic Press, Inc., 1988.
 14. Derks FW, Sanders CV. Rickettsial diseases. In: *Current Diagnosis*. Conn RB, ed. 8th ed. Philadelphia, PA: WB Saunders, 1991. 249-254.
 15. Sanders CV, Hill MK. Tuberculosis in pregnancy. In: *Infection Protocols for Obstetrics and Gynecology*. Mead PB and Hager WD, eds. Montvale, NJ: Medical Economics Publishing, 1992. 66-71.
 16. Derks FW, Sanders CV. Antibiotics: the antianaerobic drugs. In: *Obstetric and Gynecologic Infectious Disease*. Pastorek JG, ed. New York, NY: Raven Press, 1994. 659-665.
 17. Hill MK, Sanders CV. Cutaneous tuberculosis. In: *Tuberculosis*. Schlossberg D, ed. 3rd ed. New York, NY: Springer-Verlag, 1994. 225-232.
 18. Sanders CV. Approach to the diagnosis of fever and rash. In: *The Skin and Infection: A Color Atlas and Text*. Sanders CV, Nesbitt LT, eds. Baltimore, MD: Williams & Wilkins, 1995. 296-305.
 19. Hill MK, Sanders CV. Necrotizing and gangrenous soft tissue infections. In: *The Skin and Infection: A Color Atlas and Text*. Sanders CV, Nesbitt LT, eds. Baltimore, MD: Williams & Wilkins, 1995. 62-75.
 20. Hill MK, Sanders CV. Fever and rash. In: *Infectious Diseases in Critical Care Medicine*. Cunha BA, ed. New York, NY: Marcel Dekker, Inc. 533-546.
 21. Hill MK, Sanders CV. Cutaneous tuberculosis. In: *Tuberculosis and Nontuberculous Mycobacterial Infections*. Schlossberg D, ed. 4th ed. Philadelphia, PA: W.B. Saunders, 1999. 264-270.
 22. Sanders CV. Memorial for Jay P. Sanford. In: *Trans Am Clin Clima Assoc*. 2001. xliv-xlvi.
 23. Sanders CV, Lopez FA. Cutaneous manifestations of infectious diseases: approach to the patient with fever and rash. In: *Trans Am Clin Clima Assoc*. 2001. 235-252.

24. Lopez FA, Sanders CV. Rash and fever. In: *Educational Review Manual in Infectious Diseases*. Cunha BA, ed. New York, NY: Castle Connolly Graduate Medical Publishing, 2003. 1-56.
25. Lopez FA, Sanders CV. Rash and fever. In: *Educational Review Manual in Infectious Diseases*. Cunha BA, ed. 2nd edition. New York, NY: Castle Connolly Graduate Medical Publishing, 2005. 1-56.

Books

1. Sanders CV, Nesbitt LT, eds. *The Skin and Infection: A Color Atlas and Text*. Baltimore, MD: Williams & Wilkins, 1995.

Invited Review

1. Sanders CV. Review: *Cutaneous Manifestations of Infection in the Immunocompromised Host* by Mark Grossman with Jeffrey Ross. Williams & Wilkins, 1995. *Clin Infect Dis* 21:461, 1995.
2. Sanders CV. Pneumococcal Disease: A Symposium in Honor of Robert Austrian, MD—A Summary. *The American Journal of Medicine: Proceedings of a Symposium*. July 26, 1999:107(A):86S-90S. Excerpta Medica, Inc., 1999.
3. Sanders CV. Treatment of Non-tuberculous Mycobacteria. *Antibiotics for Clinicians* 4(2) 26-30. March/April 2000.
4. Lopez, Sanders CV. Review: Cutaneous infection by *Fusarium* species in healthy and immunocompromised hosts: implications for diagnosis and management by Nucci M, Anaissie E. *Clin Infect Dis*. 35:909-920. 2002. In: *MD Consult*, March 6, 2003.

Audio Tapes

1. Sanders CV. A quiz on “Drugs and Bugs.” *Audio-Digest Family Practice*. 29(16), April 27, 1981.
2. Sanders CV. Office use of newer antibiotics. *Bugs and Drugs*. Highlights of the American Academy of Family Physician’s 40th Annual Scientific Assembly Audio Digest Foundation, 36(48), 1988.

Television Appearance

1. WWL-TV. November 1, 2002, morning show. Usdin/Weil Lecture on Bioweapons.

Correspondence/ Letters to the Editor

1. Anderson JH, Sanders CV, Larson P. Exercise myoglobinuria. *N Engl J Med* 290:632, 1974.
2. Sands M, Sanders CV. *Serratia marcescens* endocarditis. *Ann Intern Med* 85:397-398, 1976.
3. Greenberg RM, Sanders CV. Amphotericin B and blastomycosis. *South Med J* 71:880-881, 1978.
4. Torres-R JR, Sanders CV, Lewis AC. Vancomycin concentration in human tissues—preliminary report. *J Antimicrob Chemother* 5:475-477, 1979.
5. Greenberg RM, Sanders CV, Stamm WE. Urethral syndrome in women. *JAMA* 245:923, 1981.
6. Scalcini MC, Sanders CV. Human-to-human transmission of *Staphylococcus aureus* endocarditis. *Arch Intern Med* 141:546, 1981.
7. Freyberg CW, Sanders CV. Candidal thrombophlebitis. *Ann Intern Med* 100:463, 1984.
8. Aldridge KE, Sanders CV, Marier RL. Determining the MICs of β -lactams for *Haemophilus*. *J Antimicrob Chemother* 19:441-442, 1987.
9. Bone RC, Metz CA, Fisher CJ Jr., Clemmer TP, Slotman GJ, Goris GB, Balk RA, the Methylprednisolone Severe Sepsis Study Group (including CV Sanders). High-dose steroids and sepsis. *New Engl J Med* 318:514-515, 1988.
10. Aldridge KE, Henderberg A, Sanders CV. Enhanced antimicrobial activity of old and new β -lactams against cefoxitin-resistant *Bacteroides fragilis* group isolates by β -lactamase inhibitors. *J Antimicrob Chemother* 25:873-875, 1990.
11. Sanders CV, Strong J. LSU would continue Charity system cooperation. *The Times-Picayune*, New Orleans, Louisiana, June 11, 1995.

Editorial

1. Sanders CV, Brown JW. *Mycobacterium marinum* infections: a problem of recognition, not therapy. *Arch Intern Med* 147:817-818, 1987.
2. Sanders CV, Kemmerly S, Farris B, Sun T. (Cover editorial) *Quality Times: A Publication of LA Health Care Review, Inc.* February 2002.

Electronic Publications

1. Lopez FA, Sanders CV. Approach to the immunocompetent patient with fever and rash. *UpToDate* CD-ROM Series. UpToDate, Inc., Wellesley, Massachusetts.

2. Lopez FA, Sanders CV. Fever and rash in HIV-infected patients. *UpToDate* CD-ROM Series. UpToDate, Inc., Wellesley, Massachusetts. 2000. Updated 2001, 2005, 2006.
3. Lopez FA, Sanders CV. Fever and rash in immunocompromised (non-HIV) patients. *UpToDate* CD-ROM Series. UpToDate, Inc., Wellesley, Massachusetts. 2001.
4. Lopez FA, Sanders CV. Fever and rash in non-HIV immunocompromised hosts. *UpToDate* CD-ROM Series. UpToDate, Inc., Wellesley, Massachusetts. 2002.

~ Last revised: December 2006